Eikon Therapeutics vs insitro (2026)
Both generate their own biological data at scale to find drug targets, and they measure different things. Eikon Therapeutics tracks how individual proteins move inside living cells with super resolution live cell microscopy, analyzed with machine learning, rather than inferring behavior from fixed samples. It was founded in 2019, is led by Roger Perlmutter, formerly head of research and development at Merck, and listed on Nasdaq in 2026. insitro, founded in 2018 by Daphne Koller, combines more than 20 petabytes of automated cellular experiments with population scale human genetics. It runs Virtual Human for target identification and TherML for designing molecules across modalities, and works with Bristol Myers Squibb and Eli Lilly. Eikon is a drug developer built on an imaging method, with more than 15 in house programs; insitro pairs cellular biology with human genetics and takes its discovery work into partnerships with larger drug companies.
- Super resolution live cell microscopy tracks individual proteins inside living cells, using optics descended from Nobel recognized single molecule imaging work.
- Machine learning is applied to protein behavior observed directly, rather than inferred from fixed or lysed samples.
- It reports more than 15 in house programs built on the platform, and raised more than $1 billion in venture capital before its 2026 Nasdaq listing.
- Virtual Human identifies causal disease targets from human genetics and large scale cellular experiments before candidate optimization.
- TherML, added with the 2026 acquisition of CombinAbleAI, designs small molecules, oligonucleotides and complex biologics.
- Its methods are published, including the POSH pooled cell painting platform in Nature Communications in 2025, and its neuroscience work includes ALS research with Bristol Myers Squibb.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Eikon Therapeutics and insitro are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Eikon Therapeutics | insitro |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2019 | 2018 |
| Headquarters | South San Francisco, CA | South San Francisco, CA |
| Website | eikontx.com | insitro.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Drug discovery company built around super resolution live cell fluorescence microscopy, applying advanced optics descended from Nobel recognized single molecule imaging work together with machine learning to track how individual proteins behave and move inside living cells, rather than inferring behavior from fixed or lysed samples.
Source: AI Health Index, September 2026
insitro is a South San Francisco AI therapeutics company founded in 2018 by Daphne Koller, built on causal biology. It combines more than 20 petabytes of automated cellular experiments (induced pluripotent stem cells, genome editing, high content phenotyping) with population scale human genetic and clinical data.
Source: AI Health Index, September 2026
Questions buyers ask
How are Eikon Therapeutics and insitro priced and sold?
For Eikon Therapeutics, the capital history is public, including a Nasdaq listing in February 2026, and as a registrant the company now files financial statements and risk factors on a cadence.
Lilly is a modality partner on the liver fat and fibrosis programs, with insitro retaining full global rights. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Eikon Therapeutics and insitro handle patient data?
In Eikon Therapeutics' case, the only document on the site is a website privacy policy, which states by its own terms that it applies to visitors and users of eikontx.com and lists what it collects from them: name, email address, IP address and browsing history.
The liver and brown fat discovery work uses UK Biobank imaging and clinical datasets. insitro has no published policy of its own on consent, retention, secondary use or model training rights for the human and partner data it holds. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Eikon Therapeutics and insitro cover?
With Eikon Therapeutics, the pipeline page names the areas and the programs: oncology, with a TLR7/8 agonist through Phase 2 and PARP1 programs including a central nervous system penetrant one, plus androgen receptor and VCP programs; and, beyond oncology, immunology and neuroscience, where the company says it invests substantial effort.
In insitro's case, the company chooses diseases where it can mine rich clinical data or build tractable cellular models, and TherML covers small molecules, oligonucleotides and complex biologics including multispecific antibodies and T cell engagers. The ophthalmology programs and the biologics work have no published results yet. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Eikon Therapeutics and insitro?
For Eikon Therapeutics, the company says its clinical programs have already shown evidence of activity in solid tumors. The assets that reached patients came from outside the platform: the lead was acquired from a partner and the PARP1 programs were in licensed, while the programs the platform originated remain preclinical.
With insitro, a brown adipose tissue study built a machine learning phenotype from UK Biobank MRI in 69,598 people, and knockdown of the prioritized target, BAT-01, cut body weight by 15% over four weeks in obese mice. In ALS, targets from the Virtual Human rescued neurite growth in iPSC derived motor neurons, and the POSH pooled cell painting CRISPR platform was published in Nature Communications in December 2025. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Eikon's assets now in clinical trials did not come from its platform. Its lead candidate, a TLR7/8 dual agonist in Phase 2/3 trials for advanced melanoma and stage IV non small cell lung cancer with pembrolizumab, was acquired from a partner, and two PARP inhibitors in early trials were licensed from Impact Therapeutics; the platform derived programs remain preclinical. No insitro candidate from its platform is shown in a clinical study. Neither sells access to its platform, and insitro works through discovery partnerships with upfront payments, research funding and milestones.